Literature DB >> 12418789

Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement.

G Robert DeLong1, Chad R Ritch, Sherri Burch.   

Abstract

One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0.15 to 0.5mg/kg) for 5 to 76 months (mean 32 to 36 months), with discontinuation trials. Response criteria are described. Family histories were obtained using the family history method in repeated interviews. Fluoxetine response, family history of major affective disorder, and unusual intellectual achievement, pretreatment language, and hyperlexia were used to define a coherent subgroup of autistic spectrum disorder. Statistical analyses were post hoc. Of the children, 22 (17%) had an excellent response, 67 (52%) good, and 40 (31%) fair/poor. Treatment age did not correlate with response. Fluoxetine response correlated robustly with familial major affective disorder and unusual intellectual achievement, and with hyperlexia in the child. Family history of bipolar disorder and of unusual intellectual achievement correlated strongly. Five children developed bipolar disorder during follow-up. Fluoxetine response, family history of major affective disorder (especially bipolar), unusual achievement, and hyperlexia in the children appear to define a homogeneous autistic subgroup. Bipolar disorder, unusual intellectual achievement, and autistic spectrum disorders cluster strongly in families and may share genetic determinants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12418789     DOI: 10.1017/s0012162201002717

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  21 in total

1.  Clinical expression of developmental coordination disorder in a large Canadian family.

Authors:  Robin Gaines; David Collins; Kym Boycott; Cheryl Missiuna; Denise Delaat; Helen Soucie
Journal:  Paediatr Child Health       Date:  2008-11       Impact factor: 2.253

Review 2.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

3.  A pharmacogenetic study of escitalopram in autism spectrum disorders.

Authors:  Thomas Owley; Camille W Brune; Jeff Salt; Laura Walton; Steve Guter; Nelson Ayuyao; Robert D Gibbons; Bennett L Leventhal; Edwin H Cook
Journal:  Autism Res       Date:  2010-02       Impact factor: 5.216

4.  TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.

Authors:  C Kağan Gürkan; Randi J Hagerman
Journal:  Res Autism Spectr Disord       Date:  2012-10-01

Review 5.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

6.  CRISPR/Cas9-mediated disruption of SHANK3 in monkey leads to drug-treatable autism-like symptoms.

Authors:  Zhuchi Tu; Hui Zhao; Bang Li; Sen Yan; Lu Wang; Yongjin Tang; Zhujun Li; Dazhang Bai; Caijuan Li; Yingqi Lin; Yuefeng Li; Jianrong Liu; Hao Xu; Xiangyu Guo; Yong-Hui Jiang; Yong Q Zhang; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2019-02-15       Impact factor: 6.150

Review 7.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Parental psychiatric disorders and autism spectrum disorders.

Authors:  Elina Jokiranta; Alan S Brown; Markus Heinimaa; Keely Cheslack-Postava; Auli Suominen; Andre Sourander
Journal:  Psychiatry Res       Date:  2013-02-04       Impact factor: 3.222

Review 9.  Advances in the treatment of fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

10.  Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism.

Authors:  Ismo Makkonen; Raili Riikonen; Jyrki T Kuikka; Hannu Kokki; Joseph P Bressler; Cathleen Marshall; Walter E Kaufmann
Journal:  J Pediatr Neurol       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.